Nasdaq-traded Chinese herb company hits near $30 billion market value after speculative surge

In this article

Regencell Bioscience Holdings

, an early-stage, Hong Kong-based bioscience company with no revenue, is the latest speculative overseas stock to attract an unusual surge in trading demand.

Shares of Regencell, which says it develops traditional Chinese herb treatments to treat childhood attention deficit hyperactivity disorder and autism, more than tripled on Monday — soaring more than 280% by the close. A 38-for-1 split declared on June 2 took effect on Monday.

The company’s year to date performance is off the charts too, having risen 46,000% in 2025. By Monday’s close, Regencell, founded in 2014 and traded on Nasdaq under the ticker ‘RGC’ since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ.